New Taipei City, Taiwan, July 22, 2025 – Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a Taiwan-based, science-driven biotechnology company focused on developing and commercializing innovative and distinct new plant-derived drugs, primarily for urinary system diseases with an initial emphasis on markets in the U.S., EU, and Asia, has announced the completion of its Nasdaq IPO ceremony and its participation in the BIO 2025 International Convention, the world’s largest biotechnology exhibition, where it interacted with other global pharmaceutical companies.

During the BIO 2025 exhibition, held in Boston, USA, from June 16 to 19, 2025, Jyong Biotech exchanged insights regarding its flagship product, MCS®-2, with various pharmaceutical players from the U.S., EU, Canada, Mexico, Japan, South Korea, China, and the Middle East. This drug targets the benign prostatic hyperplasia (BPH) market, which is expanding due to global aging and increasing obesity rates, with market size projections rising from $4.1 billion in 2020 to $9.8 billion by 2026, highlighting the urgent requirement for safe therapeutic options.

The Company’s Chairwoman, Fu-Feng Kuo, rang the Company’s NASDAQ listing bell on July 2 at the Nasdaq Stock Exchange, signifying a crucial moment for Jyong Biotech in gaining access to the global capital market. Jyong Biotech believes this strategic listing positions the Company to leverage its safety advantages in plant-based new drugs to capture opportunities in the BPH, lower urinary tract symptoms (LUTS), and prostate cancer prevention sectors, which have traditionally been dominated by synthetic drugs.

The Company aims to maximize MCS®-2 market penetration in key regions such as the U.S., Europe, and Asia through regional licensing partnerships, while simultaneously exploring opportunities in emerging markets. Utilizing the Nasdaq platform, Jyong Biotech is pursuing a dual strategy: prioritizing global licensing and sales network expansion for MCS®-2 alongside continued research and development in the urology sector to establish a comprehensive portfolio of plant-based new drug offerings.

The Company’s Chairwoman, Fu-Feng Kuo, commented: “We are confident that, from the international recognition at BIO 2025 to the successful completion of our IPO and the listing of our shares on Nasdaq, Jyong Biotech is prepared for global prominence. Grounded in clinical evidence, we are committed to addressing the urgent demand for safe medications in an aging society, thereby establishing a new standard for plant-based new drug innovation on a global scale.”

About Jyong Biotech Ltd.

Headquartered in Taiwan, Jyong Biotech Ltd. is a science-driven biotechnology company dedicated to developing and commercializing innovative and differentiated new plant-derived drugs, primarily specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia. Since its inception in 2002, the Company has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging strong research and development capabilities and a proprietary platform, the Company has been developing a series of botanical drug candidates, including its primary botanical drug candidate, MCS®-2, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates. The Company endeavors to develop and supply first-class innovative drugs to meet customers’ health needs and seeks to be a valuable business organization held in high esteem by the public.

For more information, please visit: h, .

Forward-Looking Statement

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, underlying assumptions, and other statements that are not statements of historical fact. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, those related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at . The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:
Investor Relations
WFS Investor Relations Inc.
Janice Wang
Email:
Phone:+1 628 283 9214